Bogart Wealth LLC Buys 16,305 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bogart Wealth LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 80.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 36,566 shares of the medical research company’s stock after acquiring an additional 16,305 shares during the period. Bogart Wealth LLC’s holdings in IQVIA were worth $8,665,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in IQV. CENTRAL TRUST Co boosted its stake in shares of IQVIA by 35.0% during the third quarter. CENTRAL TRUST Co now owns 690 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 179 shares in the last quarter. Great Lakes Retirement Inc. raised its holdings in IQVIA by 6.3% in the 3rd quarter. Great Lakes Retirement Inc. now owns 2,876 shares of the medical research company’s stock valued at $682,000 after buying an additional 170 shares during the last quarter. Brighton Jones LLC boosted its position in IQVIA by 9.4% during the 3rd quarter. Brighton Jones LLC now owns 1,038 shares of the medical research company’s stock worth $246,000 after buying an additional 89 shares during the period. International Assets Investment Management LLC grew its holdings in IQVIA by 26,871.1% during the 3rd quarter. International Assets Investment Management LLC now owns 40,996 shares of the medical research company’s stock worth $9,715,000 after acquiring an additional 40,844 shares during the last quarter. Finally, Sterling Investment Counsel LLC raised its stake in shares of IQVIA by 9.0% during the third quarter. Sterling Investment Counsel LLC now owns 1,828 shares of the medical research company’s stock valued at $433,000 after acquiring an additional 151 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Down 8.2 %

Shares of NYSE IQV traded down $18.70 during midday trading on Thursday, hitting $209.61. 1,114,302 shares of the stock traded hands, compared to its average volume of 1,064,179. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The business has a 50 day moving average price of $238.71 and a two-hundred day moving average price of $230.92. The company has a market cap of $38.21 billion, a PE ratio of 28.16, a P/E/G ratio of 2.26 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.22 earnings per share. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. Robert W. Baird boosted their price objective on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. Morgan Stanley increased their price target on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Evercore ISI cut their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Finally, Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $267.27.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.